(Having trouble with the video? Click here!)
Cramer doesn't ordinarily recommend fresh-faced IPOs immediately in the aftermarket. This one, however, is an exception.
"I'm talking about the IPO last Thursday of Quintiles Transnational Holdings, which now trades under the symbol Q," said the Mad Money host
Although the business is somewhat complex, Quintiles is essentially a firm to which Pharma companies outsource their clinical trial work.
"You should know that Quintiles is the largest player in this space. They've helped to develop or commercialize all of the top 50 best selling drugs out there," Cramer explained
And Quintiles is best known for the work on phase 2,3 and 4 clinical trials – "that's the sweet spot of where the big pharma players are spending their R&D budgets right now," Cramer added.
As always, Cramer has done his homework and he's discovered that by 2015 total R&D spending could total $25 billion across the industry. Largely he doesn't think Quintiles' shares reflect all of that potential.